Haloperidol

Chemical formula: C₂₁H₂₃ClFNO₂  Molecular mass: 375.864 g/mol  PubChem compound: 3559

Therapeutic indications

Haloperidol is indicated for:

Schizophrenia

Population group: only adults (18 - 65 years old)

Schizophrenia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Schizoaffective disorder

Population group: only adults (18 - 65 years old)

Schizoaffective disorder

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Delirium

Population group: only adults (18 - 65 years old)

Acute treatment of delirium when non-pharmacological treatments have failed.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Moderate to severe manic episodes associated with bipolar I disorder

Population group: only adults (18 - 65 years old)

Treatment of moderate to severe manic episodes associated with bipolar I disorder.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar I disorder

Population group: only adults (18 - 65 years old)

Treatment of acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar I disorder.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Persistent aggression and psychotic symptoms of moderate to severe Alzheimer's dementia and vascular dementia

Population group: only adults (18 - 65 years old)

Treatment of persistent aggression and psychotic symptoms in patients with moderate to severe Alzheimer’s dementia and vascular dementia when non-pharmacological treatments have failed and when there is a risk of harm to self or others.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Tic disorders

Population group: only adults (18 - 65 years old)

Treatment of tic disorders, including Tourette’s syndrome, in patients with severe impairment after educational, psychological and other pharmacological treatments have failed.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Mild to moderate chorea in Huntington's disease

Population group: only adults (18 - 65 years old)

Treatment of mild to moderate chorea in Huntington’s disease, when other medicinal products are ineffective or not tolerated.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Persistent aggression and psychotic symptoms of moderate to severe Alzheimer's dementia and vascular dementia

Population group: only elderly (65 years old or older)

Treatment of persistent aggression and psychotic symptoms in patients with moderate to severe Alzheimer’s dementia and vascular dementia when non-pharmacological treatments have failed and when there is a risk of harm to self or others.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Schizophrenia

Population group: only elderly (65 years old or older)

Schizophrenia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Schizoaffective disorder

Population group: only elderly (65 years old or older)

Schizoaffective disorder

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Delirium

Population group: only elderly (65 years old or older)

Acute treatment of delirium when non-pharmacological treatments have failed.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Moderate to severe manic episodes associated with bipolar I disorder

Population group: only elderly (65 years old or older)

Treatment of moderate to severe manic episodes associated with bipolar I disorder.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar I disorder

Population group: only elderly (65 years old or older)

Treatment of acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar I disorder.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Tic disorders

Population group: only elderly (65 years old or older)

Treatment of tic disorders, including Tourette’s syndrome, in patients with severe impairment after educational, psychological and other pharmacological treatments have failed.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Mild to moderate chorea in Huntington's disease

Population group: only elderly (65 years old or older)

Treatment of mild to moderate chorea in Huntington’s disease, when other medicinal products are ineffective or not tolerated.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Schizophrenia

Population group: only adolescents (12 years - 18 years old)

Schizophrenia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Persistent severe aggression in autism or pervasive developmental disorders

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Treatment of persistent, severe aggression in children and adolescents aged 6 to 17 years with autism or pervasive developmental disorders, when other treatments have failed or are not tolerated.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Tic disorders

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Treatment of tic disorders, including Tourette’s syndrome, in children and adolescents aged 10 to 17 years with severe impairment after educational, psychological and other pharmacological treatments have failed.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Postoperative nausea and vomiting

Population group: only adults (18 years old or older)

Combination treatment of postoperative nausea and vomiting when other medicinal products are ineffective or not tolerated.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prophylaxis of moderate to high risk of postoperative nausea and vomiting

Population group: only adults (18 years old or older)

Single or combination prophylaxis in patients at moderate to high risk of postoperative nausea and vomiting, when other medicinal products are ineffective or not tolerated.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Haloperidol is contraindicated in the following cases:

Products that prolong the QT interval

Drugs prolonging QT interval

Uncorrected hypokalaemia

Hypokalemia

History of ventricular arrhythmia

Ventricular arrhythmia

History torsades de pointes

Torsades de pointes

Uncompensated heart failure

Cardiac failure

Recent acute myocardial infarction

Acute myocardial infarction

Known QTc interval prolongation or congenital long QT syndrome

at least one of
Long QT syndrome
Prolonged QT interval

Progressive supranuclear palsy

Progressive supranuclear palsy

Dementia with Lewy bodies

Senile dementia of the Lewy body type

Parkinson's disease

Parkinson's disease

Central nervous system (CNS) depression

Central nervous system depression

Comatose state

Coma

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2017: HALOPERIDOL Solution for injection
Structured Product Labeling (SPL) 2020: HALDOL DECANOATE Solution for injection
Summary of Product Characteristics (SPC) 2017: HALOPERIDOL Oral solution
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈